359 related articles for article (PubMed ID: 36466855)
1. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
2. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
4. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
He Q; Yang J; Jin Y
Front Immunol; 2022; 13():869993. PubMed ID: 35493518
[TBL] [Abstract][Full Text] [Related]
6. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes.
Yan J; Cao J; Chen Z
BMC Cancer; 2021 Feb; 21(1):175. PubMed ID: 33602168
[TBL] [Abstract][Full Text] [Related]
7. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
8. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
9. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
[TBL] [Abstract][Full Text] [Related]
10. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
11. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
13. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
16. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.
Wu Z; Guo L; Wan L; Xu K; Luo L; Wen Z
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11891-11905. PubMed ID: 37410140
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
[TBL] [Abstract][Full Text] [Related]
19. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
20. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
Dai K; Liu C; Guan G; Cai J; Wu L
BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
